Exploiting the dependence of cancer cells on transcription can be used as an effective strategy for targeting aggressive and therapeutically recalcitrant tumors. Wang et al. show that inhibiting transcription using THZ1, a small-molecule inhibitor of cyclin-dependent kinase CDK7, induces apoptotic cell death in triple-negative breast cancers.
Large-scale, deep-sequencing-based genomic analyses have revealed a surprising level of genetic heterogeneity in cancers. In some cancers, ''driver'' mutations in key oncogenes can be parsed out from the background of genetic heterogeneity. Some of these oncogenes (such as BRAF and EGFR) encode mutant proteins that provide opportunities for rational targeting by drugs (for instance, targeting BRAF V600E by Vemurafenib and Dabrafenib in melanoma; targeting EGFR L858R or exon 19 deletions by Afatinib and Gefitinib in non-small-cell lung cancer) (Bollag et al., 2012; Sordella et al., 2004) . For other cancers, such as triple-negative breast cancer (TNBC), definitive driver mutations have not been identified and thus lack targeted therapies. In spite of a high level of genetic heterogeneity, TNBCs maintain a characteristic and readily identifiable pattern of gene expression. In this issue of Cell, Wang et al. (2015) hypothesize that maintenance of a uniform gene expression program in TNBCs requires continually active transcription, which might make these cancers highly sensitive to drugs that inhibit transcription ( Figure 1A) .
Recent studies using small-molecule inhibitors of the transcriptional machinery have shown promising selectivity for cancer cells and potent antiproliferative effects. For example, targeting bromodomain and extra-terminal proteins (BET) family members, such as BRD4, with JQ1 has exploited the dependence of certain cancers on the transcription of critical driver oncogenes (e.g., c-Myc), rendering these cancers sensitive to transcriptional inhibition (Delmore et al., 2011) . More recently, THZ1, a selective covalent inhibitor of cyclin-dependent kinase CDK7, has been shown to be effective in inhibiting the growth of several cancers, such as T cell acute lymphoblastic leukemia , MYCN-amplified neuroblastoma , and small-cell lung cancer . Wang et al. (2015) explore the therapeutic potential of targeting CDK7 in TNBC, a therapeutically recalcitrant subtype of breast cancer that does not express estrogen receptors (ERs, the target of the first-line therapeutic Tamoxifen), progestin receptors (PRs), or the HER2 receptor (ERBB2; a receptor tyrosine-protein kinase). Using THZ1 and CRISPR/ Cas9-mediated gene editing, the authors observe that TNBC cells, but not ER-positive/PR-positive breast cancer cells, are highly dependent on the transcriptional functions of CDK7. Inhibition of CDK7 with THZ1 promotes apoptotic cell death in both TNBC cell lines and patientderived tumor samples.
CDK7 is a cyclin-dependent kinase (CDK) and a subunit of the multi-protein basal transcription factor TFIIH. As such, it plays dual roles in the regulation of cell-cycle progression and transcription. As a component of the CDK Activating Kinase (CAK), CDK7 is involved in control of the cell cycle by phosphorylating other cell-cycle CDKs, such as CDK1 and CDK2 (Malumbres, 2014) . As a component of TFIIH, CDK7 regulates transcription initiation by phosphorylating serines 5 and 7 of the heptapeptide repeat in the C-terminal domain (CTD) of the largest subunit (RPB1) of RNA polymerase II (Pol II) (Malumbres, 2014 ) ( Figure 1B ). In their study, Wang et al. (2015) demonstrate that THZ1-mediated inhibition of CDK7 does not alter the cell cycle in TNBC cells, suggesting that the sensitivity of TNBCs to THZ1 is mediated through transcriptional inhibition.
Following from their initial observations, the authors postulate that TNBCs are dependent on the uninterrupted transcription of a key set of genes whose expression supports the cancer phenotype. Indeed, they identified a set of 450 genes whose expression is highly sensitive to inhibition of CDK7 by THZ1, which they refer to as an ''Achilles cluster'' of TNBC-specific genes ( Figure 1A ). Gene ontology analyses revealed that this gene set is enriched for factors involved in signaling and transcription regulation, including genes encoding signaling molecules and transcription factors with established roles in breast cancer (e.g., TGFB, STAT, and WNT). Interestingly, these genes are associated with large clustered enhancer regions (so-called ''super enhancers''), which are required to drive high-level expression of these genes. The authors posit that targeting CDK7-dependent transcription is an effective way to collectively suppress the expression of multiple genes that are critical for the proliferation of TNBC cells. As such, this gene set may have utility as a prognostic signature for tumors that can be treated effectively with THZ1.
Recent studies have suggested that cancer cells have a higher overall transcriptional output than non-malignant cells (Lin et al., 2012) . This may increase the likelihood of these cancer cells to engage in oncogenic pathways ( Figure 1C ). Inhibition of transcription may, therefore, reduce the transcriptional output of cancer cells to levels that are less likely to feed into oncogenic pathways ( Figure 1C ). However, due to the universal role and biological importance of transcription in all cells, targeting transcription as a therapeutic strategy may be challenging due to the potential lack of selectivity for cancer cells over normal cells. Therefore, it is imperative to determine if the therapeutic window between efficacy and toxicity for malignant and non-malignant cells is large enough to produce a therapeutically efficacious effect ( Figure 1D ).
This situation is analogous, in some respects, to the use of DNA-damaging therapeutics. All cells need to maintain a certain level of genome integrity to survive, but highly proliferative cells, such as cancer cells, are more sensitive the effects of DNA-damaging drugs. In fact, this is the basis of synthetic lethality with PARP inhibitors in BRCA1/2-depleted cancers. While current chemotherapeutic agents used to induce DNA damage exploit the requirement for cancer cells to frequently replicate their genomes, a similar dependence on transcription can now be exploited with transcription inhibitors, such as THZ1.
In spite of recent advances in genomic sequencing, clear driver mutations have yet to be discovered for TNBCs. While ER-positive/PR-positive breast cancers are effectively treated with hormone therapies, the more aggressive TNBCs lack targeted therapies, and cytotoxic chemotherapy remains the standard treatment (Mayer et al., 2014) . Thus, THZ1 and its derivatives are promising candidates for the treatment of TNBCs. Wang et al. (2015) have developed an analog of THZ1 (THZ2) with improved pharmacokinetics that has few side effects in mouse xenograft models, which may be more useful clinically. The growth-promoting pathways that are activated in cancer cells involve multiple redundancies. Therefore, the use of a targeted therapeutic agent that selectively inhibits one pathway may be undermined by the activation of a compensatory pathway (Mayer et al., 2014) . The strategy of targeting transcription more generally may be effective in these cases. Moreover, combining targeted agents with transcriptional inhibitors may be an effective approach for the treatment of TNBC, which may minimize therapeutic resistance of these difficult-to-treat cancers. If THZ1-based therapy can be effectively translated into the clinic, the identification of biomarkers, perhaps an enhancer signature, that can predict if a given tumor will be sensitive to CDK7 inhibition will be essential.
In sum, this study highlights the enormous potential for targeting transcriptional addiction in aggressive tumors. A) Cancer cells are characterized by increased genomic heterogeneity compared to normal cells. In some cancers, driver mutations in key oncogenes can be targeted therapeutically to inhibit cancer cell growth or induce apoptosis. In cancers with no clear driver mutations, such as TNBC, inhibitors such as THZ1 can be used to target ''transcription addiction'' to a set of ''Achilles cluster'' genes that encode for factors involved in signaling and transcription regulation. Many cancer cells can be killed with DNA-damaging agents, which wreak havoc on the genome. (B) THZ1 covalently binds to and inhibits the activity of CDK7 (a subunit of TFIIH), preventing phosphorylation of the C-terminal domain (CTD) of the largest subunit (RPB1) of RNA polymerase II (Pol II) and inhibiting productive transcription initiation. (C) Current models posit that tumor cells have a higher overall transcription output than normal cells, allowing for more opportunities to engage oncogenic pathways. General inhibition of transcription can have a therapeutic benefit by decreasing the overall transcription output to levels similar to those observed normal cells. (D) Due to the universal role and biological importance of transcription in all cells, the therapeutic window between efficacy and toxicity for malignant and non-malignant cells will determine if THZ1 can be used to treat human patients.
Cell 163, September 24, 2015 ª2015 Elsevier Inc. 29 Retroviral restriction is a complex phenomenon that, despite remarkable recent progress, is far from being well understood. In this Preview, we introduce an insightful study by Yang et al. that represents the first attempt to identify the global determinants of retroviral repression in pluripotent mammalian cells.
To protect their genomic integrity, animals control retroviral infections by establishing heritable epigenetic silencing of the integrated provirus in early embryonic development. In mouse embryonic stem cells (ESCs), KAP1 (Trim28) is targeted to newly integrated Moloney murine leukemia virus (MMLV) by the Krueppelassociated box (KRAB) zinc finger protein ZFP809. KAP1, in turn, recruits histonemodifying enzymes, including the histone methyl transferase SETDB1 (ESET), that deposit repressive histone 3 lysine 9 trimethylation (H3K9me3) marks at the provirus (Figure 1) (Matsui et al., 2010; Rowe et al., 2010; Wolf and Goff, 2009) . The KRAB/KAP1 system also represses endogenous retroviruses (ERVs), which are potentially hazardous remnants of retroviral germline infections (Matsui et al., 2010; Rowe et al., 2010; Wolf et al., 2015) . Additionally, several cofactors of the KRAB/KAP1 system, but also KAP1-independent retroviral repression pathways, have been identified over the last few years. Indeed, the abundance and sequence diversity of exogenous and endogenous retroviruses likely drove evolution of complex and partially redundant repression mechanisms that keep these elements under control. Moreover, some ERVs have been adapted as new regulatory elements and, in some cases, have re-wired entire transcriptional networks (Macfarlan et al., 2012) . Retroviral repression mechanisms might therefore also regulate transcription of cellular genes. Despite recent progress in the field, deciphering the complexity and interconnectivity of retroviral repression pathways and networks remains an outstanding problem of mammalian genome biology. The Resource article by Yang et al. (2015) performs a genome-wide small interfering RNA (siRNA) knockdown screen in a first attempt to determine in a global manner the components of retroviral repression machinery in mammalian pluripotent cells.
The siRNA screen was performed using a MMLV reporter that is repressed by ZFP809/KAP1 and is therefore primarily aimed at identifying cofactors acting upand downstream of the KRAB/KAP1 system, but also at potentially overlapping KAP1-independent repression pathways. Apart from previously known factors, including ZFP809, KAP1, and SETDB1, hundreds of new repression candidates were identified. As expected, many candidates are associated with chromatin modification, DNA methylation, and regulation of transcription. Additionally, the screen identified genes involved in protein sumoylation, DNA repair, and DNA replication and even factors located outside of the nucleus (e.g., plasma membrane, cytoskeletal, and organelle proteins). These findings highlight the complexity of retroviral restriction networks in mammalian cells, although many of these factors may not primarily, specifically, and/or directly repress retroviruses. Without a doubt, the provided candidate list is a potentially valuable resource for future studies that may address how these factors mediate retroviral restriction and ultimately help us to better understand how epigenetic silencing of retroviruses is established, maintained, and inherited during development.
Two of the newly identified repression mechanisms are subsequently analyzed
